Piauhy Labs opens its research facility at Biocant Park. The medical Cannabis company is set to begin its new research in the Science and Technology Park located in Cantanhede, in the centre of Portugal.
Created in 2019, Piauhy Labs received its pre-license from Infarmed, the Portuguese pharmaceutical regulatory agency, in 2020. Since then, the company has also submitted a request for a R&D license for controlled substances to the regulatory agency, which will serve as the kickstarter for new pharmaceutical developments at Biocant Park.
With its most recent partnership, Piauhy Labs hopes to conduct further research on the Cannabis plant and its compounds, advancing in its goal of producing effective treatments for different types of illnesses. Through analytical chemistry operations conducted at Biocant Park, the company will be able to identify and extract the different components of the plant for therapeutic use.
The Cannabis sativa plant, within its different species, has a complex matrix of over 550 substances, including terpenes, carbohydrates, and cannabinoids. The extraction of part of these cannabinoids and terpenes, along with their proper identification, may lead to greater discoveries regarding the pharmaceutical application of these compounds on patients suffering from several different kinds of diseases. The identification of these substances will be carried out using gas chromatography and high-performance liquid chromatography equipment. The medical cannabis company will then study the substances originating from the plant and their efficacy and potential for the treatment of neural diseases such as epilepsy, Alzheimer’s, and autism.
Furthermore, regarding the extraction of Cannabis compounds for therapeutic use, Piauhy Labs also intends to begin working on another new research project, which will involve the creation of…